{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T21:30:41Z","timestamp":1780522241465,"version":"3.54.1"},"reference-count":5,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,1,25]],"date-time":"2013-01-25T00:00:00Z","timestamp":1359072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2013,5]]},"abstract":"<jats:sec>\n                    <jats:title>What's known on the subject? and What does the study add?<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            Intravesical bacille\n                            <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>\n                            almette\u2010\n                            <jats:styled-content style=\"fixed-case\">G<\/jats:styled-content>\n                            u\u00e9rin (\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            ) is generally considered to be contraindicated in immunologically compromised patients with bladder cancer because it may be ineffective and potentially toxic. Therefore, there is little experience with\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            in individuals with impaired immune systems.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            The present study provides evidence that intravesical\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            is safe and effective in the short term against non\u2010muscle\u2010invasive bladder cancer affecting patients who were receiving immunosuppressive medications. This included anti\u2010rejection drugs to support a solid organ transplant, high\u2010dose steroids for autoimmune inflammatory diseases, and the first description of\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            use in patients who were receiving concomitant systemic chemotherapy for unrelated malignant neoplasms.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            To investigate the outcomes of bacille\n                            <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>\n                            almette\u2010\n                            <jats:styled-content style=\"fixed-case\">G<\/jats:styled-content>\n                            u\u00e9rin (\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            ) therapy in patients with bladder cancer who were immunologically compromised.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            In all, 45 immunosuppressed patients with high\u2010grade non\u2010muscle\u2010invasive bladder cancer received\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            therapy. Twelve had functioning organ transplants, 23 were undergoing systemic chemotherapy for unrelated cancers, and 10 were taking steroids for autoimmune or related diseases.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Patients received a 6\u2010week induction course of\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            therapy. Relapsing patients were eligible for retreatment.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>All patients were followed for median (range) of 40 (12\u201372) months.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            End points were response to\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            and 5\u2010year recurrence\u2010free, progression\u2010free and overall survival rates.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            In all, nine of the 12 transplant patients responded completely to one or two cycles of\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            compared with 99% (32\/33) of other immunosuppressed patients.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Half the patients with unrelated cancers and autoimmune diseases recurred vs all but one of the transplant patients (\n                            <jats:italic>P<\/jats:italic>\n                            = 0.008). Of the 12 transplant patients, six of 12 progressed vs five of 33 (15%) of the other patient groups (\n                            <jats:italic>P<\/jats:italic>\n                            = 0.02).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Five patients died (11%), two of bladder cancer (both in transplant patients), and three of unrelated causes.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            was well tolerated. None of the patients developed bacterial or\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            sepsis.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Although this is largest series evaluating\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            in transplant and other immune\u2010suppressed patients, it represents few patients and results must be interpreted with caution.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            We conclude that intravesical\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            is safe and effective in immunologically compromised patients with bladder cancer.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Transplant patients fare worse and should be considered for early cystectomy if they fail\n                            <jats:styled-content style=\"fixed-case\">BCG<\/jats:styled-content>\n                            therapy.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2012.11778.x","type":"journal-article","created":{"date-parts":[[2013,1,25]],"date-time":"2013-01-25T12:23:57Z","timestamp":1359116637000},"page":"984-987","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Intravesical bacille\n                    <scp>C<\/scp>\n                    almette\u2010\n                    <scp>G<\/scp>\n                    u\u00e9rin (\n                    <scp>BCG<\/scp>\n                    ) in immunologically compromised patients with bladder cancer"],"prefix":"10.1111","volume":"111","author":[{"given":"Harry W.","family":"Herr","sequence":"first","affiliation":[{"name":"Department of Urology Memorial Sloan\u2010Kettering Cancer Center  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Dalbagni","sequence":"additional","affiliation":[{"name":"Department of Urology Memorial Sloan\u2010Kettering Cancer Center  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,1,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.03.017"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.03.051"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0012.2002.01152.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000090748.32764.0F"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/256985"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2012.11778.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2012.11778.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:37:38Z","timestamp":1761748658000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2012.11778.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,25]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["10.1111\/j.1464-410X.2012.11778.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2012.11778.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,25]]},"assertion":[{"value":"2013-01-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}